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Abstract
Deep venous thrombosis (DVT) and its sequel, pulmo nary
em bolism (PE), are serious complications of stroke. There are
pharmacological and physical methods to prevent these com-
plications. The authors review the lite rature and present the
current state of knowledge re garding the effectiveness of each
of the DVT and PE prevention methods in stroke patients and
cite current Polish, European and American recommendations
re garding this issue. Heparins are the method of choice for the
prevention of venous thromboembolism in both ischaemic and
haemorrhagic stroke patients. 
Key words: venous thromboembolism, deep venous throm-
bosis, stroke, prophylaxis.
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St reszc zen ie
Zakrzepica ¿y³ g³êbokich koñczyn i jej konsekwencja – zato-
rowoœæ p³ucna, s¹ powa¿nymi powik³aniami udaru mózgu. 
Istniej¹ farmakologiczne i fizyczne metody zapobiegania tym
powik³aniom. Autorzy dokonuj¹ przegl¹du piœmiennictwa
i prezentuj¹ aktualny stan wiedzy na temat skutecznoœci ka¿dej
z metod stosowanych w profilaktyce zakrzepicy ¿y³ g³êbokich
koñczyn i zatorowoœci p³ucnej u chorych po udarze mózgu,
a tak¿e cytuj¹ aktualne zalecenia polskie, europejskie i amery-
kañskie. Stosowanie heparyn jest metod¹ z wyboru w zapo-
bieganiu powik³aniom zakrzepowo-zatorowym u unierucho-
mionych chorych z udarem mózgu, zarówno niedokrwiennym,
jak i krwotocznym. 
S³owa kluczowe: zakrzepica ¿y³ g³êbokich koñczyn dolnych,
zatorowoœæ p³ucna, udar mózgu, profilaktyka.
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Introduction
The importance of post-stroke deep venous
thrombosis
Deep venous thrombosis (DVT) and its sequel, pul-
monary embolism (PE), are important causes of illness 
and death after stroke [1]. Patients who are immobile, with
significant weakness of the limbs and with a prior histo-
ry of DVT are at greatest risk of DVT development [2].
In studies using magnetic resonance imaging to detect
thrombus, DVT occurred in 40.2% of stroke patients
within the first three weeks, of which 17% was above-
knee DVT [3]. However, studies in which Doppler
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ultrasound was used as a screening technique suggest
a lower frequency of above-knee DVT of perhaps ‘only’
10-11%, although the types of patients included and the
duration and timing of follow-up influence the estimates
[4,5]. Some studies suggest even that the frequency of
both distal and proximal DVT reaches slightly more than
11% (above-knee DVT – 1%) [6]. Discrepancies in the
results are due to methodological differences of those
studies. Moreover, patients with acute stroke and in -
creased C-reactive protein (CRP) level seem to be at sub-
stantial risk of new clot formation [7]. Most DVTs are
clinically silent so symptomatic ones seem to be the tip
of the iceberg of the problem [7]. Clinically not recog-
nized DVTs still may cause important complications.
Above-knee DVT is associated with great risk of PE and
is responsible for 90% of total PE. Clinically evident PE
in the early phase of stroke has been variably estimated,
depending on the type of study: to affect one to 16% of
patients in prospective trials [8,9], and 3-30% in obser-
vational studies [10]. 
Deep venous thrombosis prophylactic methods
There are pharmacological (unfractionated heparin
– UFH, low-molecular-weight heparins – LMWH,
oral anticoagulants, new oral anticoagulants, dextrans)
and physical methods (graduated compression stock-
ings [GCS], intermittent pneumatic compression [IPC]
devices) which aim to reduce the risk of venous throm-
boembolism (VTE). Proper hydration and early mobi-
lization are also regarded as prophylactic methods.
Pharmacological methods 
to prevent post-stroke venous
thromboembolism 
Heparins
There is a large amount of data supporting the use
of anticoagulants (heparins in perioperative period fol-
lowed by new and old oral anticoagulants) in patients
undergoing surgical procedures, to prevent thrombo -
embolic complications; hence they are strongly recom-
mended in this group of patients [11].
The situation regarding the use of anticoagulants 
in the prevention of VTE in stroke patients is more 
complicated, as there is lack of studies evaluating their
efficacy and safety in this group of patients, and hae mor-
rhagic complications are relatively frequent. The Coch -
rane review identified four trials which compared
LMWH (enoxaparin or certoparin), and one trial com-
pared an unspecified LMWH with standard unfrac-
tionated heparin in stroke patients [12]. Allocation to
LMWH or heparinoid was associated with a significant
reduction in the odds of deep vein thrombosis compared
with standard unfractionated heparin (odds ratio [OR]
0.55, 95% confidence interval [CI] 0.44 to 0.70). How-
ever, the number of major events (pulmonary embolism,
death, intracranial or extracranial haemorrhage) was too
small to provide a reliable estimate of the benefits and
risks of LMWH or heparinoids compared with standard
UFH for these, arguably more important, outcomes.
Unfractionated heparins were extensively studied in
the 1990s. However, evidence from the International
Stroke Trial [13] shows that even low dose heparin
(5,000 units twice daily) is associated with a significant
excess of symptomatic intracranial and extracranial bleeds
which offset any other advantages heparin may have in
recurrent ischaemic stroke and fatal PE. What is more,
compared with 5000 IU b.i.d. heparin, 12,500 IU b.i.d.
heparin was associated with significantly more transfused
or fatal extracranial bleeds, more haemorrhagic strokes,
and more deaths or non-fatal strokes within 14 days
(12.6% vs. 10.8%). However, it should be stressed that
in this study PE prevention was additionally analyzed as
a secondary endpoint. 
There have been no studies comparing UFH with
LMWH in VTE prevention as a primary endpoint in
stroke patients. The largest trial to date was published
in 2007 (PREVAIL trial), and compared the effective-
ness and safety of UFH with LMWH [14]. It demon-
strated that LMWH (enoxaparin 40 mg daily) was
probably more effective than standard heparin (5000 IU
twice daily) in preventing mainly asymptomatic DVTs
but it was not powered to identify clinically significant
differences in risk. More importantly, it does not pro-
vide any evidence that routine heparin or LMWH use
is associated with net benefit, because there was no ‘avoid
any heparin’ control group.
The newest study (EXCLAIM study) evaluated the
use of enoxaparin 40 mg for 10 ± 4 days, in acutely ill
patients (including patients with acute ischaemic stroke)
[15]. Patients were randomized to double-blind enoxa-
parin 40 mg daily or placebo for a further 28 ± 4 days
in VTE prophylaxis. In total, 389 of 5963 (6.5%) ran-
domized patients had ischaemic stroke. Some of them
(n= 198) received extended-duration prophylaxis and
191 received placebo. Extended-duration enoxaparin
significantly reduced VTE incidence versus placebo
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(2.4% vs. 8.0%; absolute risk difference, –5.6%; 95% CI:
–10.5% to –0.7%), but it was associated with an in -
creased incidence of major bleeding (1.5% vs. 0% in
enoxaparin and placebo groups; absolute risk difference,
+1.5%; 95% CI: –0.2% to 3.2%).
Authors of the literature review suggest that, despite
the lack of large clinical trials in acute stroke patients,
preferential use of enoxaparin over UFH for the pre-
vention of VTE after acute ischaemic stroke may lead
to reduced VTE rates and concomitant cost savings in
clinical practice [16].
Both European and American guidelines recom-
mend the use of heparins (UFH and LMWH) to pre-
vent VTE in stroke patients, but suggest their use most-
ly in those considered to be at high risk of VTE and low
risk of bleeding – interpretation of this recommenda-
tion may be problematic and controversial [17,18].
Most recent Polish guidelines on VTE prophylaxis 
suggest the use of heparins as a method of choice in both
ischaemic and haemorrhagic stroke patients [19].
LMWH should be preferred over UHF [19]. 
Oral anticoagulants
Anticoagulants and new oral anticoagulants have not
been evaluated for VTE prophylaxis in acute stroke
patients. Available studies included patients in the reha-
bilitation phase following cerebral infarction and were
flawed by a significant number of losses to follow-up
evaluation [20]. Anticoagulants are contraindicated in
the acute phase of both ischaemic and haemorrhagic
stroke to prevent VTE and as a secondary stroke pre-
vention [21]. This may explain the lack of studies eval-
uating anticoagulants in VTE prevention in acute stroke
patients. Nevertheless, patients with confirmed DVT or
PE should receive a therapeutic dose of LMWH or
UFH followed by oral anticoagulants, which is consis-
tent with the treatment of patients with other acute med-
ical illnesses [19,21]. 
Aspirin
In 1977, aspirin (at a dose of 600 mg twice daily) was
shown to reduce the risk of VTE, when it was given to
patients after they had undergone hip arthroplasty [22].
Thirty-five years later, guidelines still include aspirin as
one of the options for preventing VTE after orthopaedic
surgery [23]. Other trials have demonstrated that aspirin
is possibly effective in preventing DVT and PE after 
other surgical procedures [24,25]. However, to date
there are no data to support the use of aspirin to prevent
DVT and/or PE in acute stroke pa tients. The results of
the International Stroke Trial (IST) [13] and the Chi-
nese Acute Stroke Trial (CAST) [26] suggest that
aspirin should be started in all patients with excluded
haemorrhagic and proven ischaemic stroke as soon as
possible since it is associated with a reduced risk of death
and recurrence of stroke within the first month. How-
ever, in those studies PE was a secondary endpoint which
should be stressed, whilst the primary endpoint was any
further stroke or death. In a meta-analysis of both of
those studies (IST and CAST) the effect of aspirin in
PE prevention was unclear as groups with PE were too
small (30 in the aspirin group vs. 41 in controls) to draw
any firm conclusions [27]. In the IST, although VTE
was not a primary endpoint, aspirin was associated with
risk reduction of PE in the first two weeks from 0.8% to
0.6% (2p = 0.08, odds reduction 26% (95% CI: 48%
reduction to 4% increase) [13]. Nevertheless, aspirin
should not be considered as a VTE prevention method
as there are not enough data to support its use in DVT
prevention [28]. A Cochrane review identified two small
trials including 133 patients (fewer than 0.3% of the par-
ticipants included in the overall review) and showed that
antiplatelet therapy did not reduce the risk of VTE (OR:
0.78; 95% CI: 0.36-1.67) [29]. Therefore, all patients
with stroke, except those with haemorrhagic stroke or
with other contraindications to aspirin, should be treat-
ed with aspirin but this should be regarded only as the
secondary stroke prevention and not VTE prevention of
immobile, post-stroke patients [17,18].
For many years, aspirin was not recommended in
stroke patients as a VTE prophylactic method due to the
lack of data to support its effectiveness in VTE prophy-
laxis [30]. In the newest version of the American College
of Chest Physicians (ACCP) recommendations accept-
ed by Polish experts in 2012, aspirin is one of the VTE
prophylaxis options, which seems controversial [19].
Haemodilution and dextrans
Haemodilution has been extensively studied as
a potential prevention method for VTE complications
in acute ischaemic stroke patients. A meta-analysis of
the available randomized controlled trials (RCTs) sug-
gests that it confers no benefit overall [31]. However,
this analysis demonstrated that haemodilution was asso-
ciated with a strong trend towards fewer DVTs. On the
other hand, it is widely assumed that dehydration pre-
disposes to VTE and this fits with one small observa-
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tion study evaluating a greater risk of dehydrated post-
stroke patients for VTE [32]. 
The use of dextrans in VTE prevention is not rec-
ommended in stroke patients as there are no data to sup-
port its effectiveness [17,18].
Nevertheless, in many stroke units hydration is an
important part of VTE prevention, despite the fact that
it is not recommended by the newest Polish and Amer-
ican neurological society guidelines; hence this should
not be a routine clinical practice [18,21]. 
Physical methods of venous 
thromboembolism prevention 
Early mobilization
Early mobilization is a standard procedure in surgi cal
patients, to prevent thromboembolic complications [11].
It is also a part of DVT prophylaxis in post-stroke
patients in many centres, although there is an ongoing
debate about the definition and effectiveness of this
method [33]. Nevertheless, this method is recommend -
ed by European Stroke Organization guidelines [17],
as well as by the newest Polish guidelines of stroke treat-
ment and prevention published in 2012 [21]. The lat-
est American guidelines do not mention the use of this
method [18]. There have been no trials evaluating 
the effectiveness of this method in VTE prevention in
stroke patients. Moreover, the ongoing AVERT trial 
(A Very Early Rehabilitation Trial for Stroke) will also
not answer whether this method is effective in VTE pre-
vention as the aim of this study is to test its effect on
functional outcomes but not VTE [34].
Immobile patients are at great risk of DVT [2]. It
is therefore not surprising that early mobilisation and
exercises involving foot extension improve venous flow
and are a promising prophylactic measure. However,
there is still no reliable evidence to support this thesis.
Ongoing trials evaluating the effectiveness of early
mobilisation hope to show some effectiveness [34].
Graduated compression stockings
Graduated compression stockings are commonly
used in several surgical wards, as their effectiveness has
been proved in patients after surgical procedures. At
least three systematic reviews of randomised control
studies (RCTs) evaluating GCS have concluded that
graduated compression stockings are effective in peri-
operative patients [35-37]. In 1994, a systematic review
of GCS was published (11 trials, n = 1752). In this
review, the use of GCS in post-surgical patients was
associated with 68% (95% CI: 53-73%) risk reduction
of DVT. A more recent systematic review showed a 62%
(95% CI: 52-70%) risk reduction of DVT in 2582 pa -
tients randomised in 18 trials [37]. The latter review
demonstrated a 53% (95% CI: 3-83%) reduction in PE
amongst 1466 patients entered into 12 trials. Only two
of the trials included randomised high-risk medical
(rather than surgical) patients [38,39]. Too few DVTs
occurred to provide any reliable estimate of their effec-
tiveness in this context.
The first RCT to evaluate GCS in stroke patients
was published in 2000 [39]. In this trial, 98 patients
with an acute stroke were randomly allocated to one of
three treatment groups: routine care, routine care plus
Kendall TED stockings, or routine care plus Brevett
TX stockings. At randomisation 9/97 (9%) already had
detectable popliteal thrombus with the use of Doppler
ultrasound (USG) and five additional patients had
detectable DVT by day 5 to 9. Thus 14/97 (14%) of pa -
tients had DVTs within 10 days of stroke onset. Of the
five DVTs which occurred after randomisation, four
occurred in the non-stocking group. Fifteen of 65 pa -
tients allocated to full length stockings and 10 of 32 al -
located to the non-stocking group either died or had 
DVTs detected in Doppler ultrasound (OR 0.66; 
95% CI: 0.26-1.70). This small single centre trial was
underpowered to demonstrate that differences between
treatment groups were statistically significant.
In a large clinical trial published in 2009 [5] which
was designed to evaluate the effectiveness of thigh-length
GCS (n= 1256) versus routine care (n= 1262), pro x-
imal DVT on USG examination at 7-10 days after stroke
was found in 10.0% and 10.5% of patients, res pectively.
The primary outcome was the occurrence of symptomatic
or asymptomatic DVT in the popliteal or femoral veins.
The primary outcome occurred in 126 (10.0%) patients
allocated to thigh-length GCS and in 133 (10.5%) allo-
cated to avoid GCS, which resulted in a non-significant
absolute reduction in risk of 0.5% (95% CI: –1.9% to
2.9%). In the stocking-wearing group skin breaks, ulcers,
blisters, and skin necrosis were significantly more com-
mon than in those allocated to avoid the use of GCS 
(64 [5%] vs. 16 [1%]; OR 4.18, 95% CI: 2.40-7.27).
In the Clots 2 trial (Clots in Legs Or sTockings after
Stroke) the authors compared the effectiveness of thigh-
length stockings with that of below-knee stockings for
preventing proximal DVT in immobile, hospitalized
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patients with stroke. 1552 patients received thigh-length
stockings and 1562 patients received below-knee stock-
ings to wear while they were in the hospital. USG of the
lower extremities was performed 7-10 days after stroke.
The primary outcome was symptomatic or asymptomatic
DVT in the popliteal or femoral veins, detected on either
scan. The primary outcome occurred in 6.3% of patients
who received thigh-length stockings and in 8.8% 
who received below-knee stockings (absolute difference,
2.5 percentage points [95% CI: 0.7 to 4.4 percentage
points]; P= 0.008), an odds reduction of 31% (95% CI:
9% to 47%) [40].
Generally, there is no great risk associated with wear-
ing GCS. However, in patients with severe peripheral
vascular disease and/or peripheral neuropathy they are
contraindicated because their use can cause skin necro-
sis and occasionally this has necessitated even amputa-
tion [41,42]. Patients with stroke are more likely than
surgical patients to suffer diabetes and peripheral vas-
cular disease. Perhaps more significant than this small
risk is the much more common experience of patients
and nursing staff that GCS, especially the full length,
are uncomfortable and may be difficult to apply in pa -
tients with limb weakness. In addition, many stroke
patients are incontinent of urine and/or faeces, which
can lead to soiling of the stockings and this can cause
more problems with the underlying skin and great er dis-
comfort. This was confirmed in the CLOTS 1 trial [5].
Both European and American guidelines recom-
mend that GCS should not be routinely used in stroke
patients [17-19,21].
Intermittent pneumatic compression
Intermittent pneumatic compression (IPC) devices
comprise a wide range of systems, including multi-
chamber or monochamber devices acting toward either
the whole leg or only the calf, applying pressure either
sequentially or uniformly. There is also a plantar com-
pression system. The sleeves of those devices may be
short, wrapping around just the lower leg, or long to
wrap around the thigh as well. They are inflated one side
at a time to compress the leg at intervals. Some types
inflate sequentially, first around the lower leg and then
the upper, to increase venous flow of the blood from the
leg. The frequency of inflation can be fixed, or in more
sophisticated systems, varies depending upon the rate
of venous refill. The boots may be used in combination
with graduated compression stockings.
Intermittent pneumatic compression is thought to
reduce the risk of venous thrombosis by increasing the
flow of venous blood through the deep veins of the leg
to reduce the likelihood of thrombosis and stimulating
release of intrinsic fibrinolytic substances [43].
Intermittent pneumatic compression devices, like
graduate compression stockings, have mainly been used
in surgical patients during and immediately after oper-
ations. A systematic review of the literature identified
22 randomised trials of IPC which included a total of
2779 patients. Use of IPC was associated with a 64%
reduction in the odds of DVT (p< 0.00001) [37]. In
19 trials including 2255 patients assessing IPC as mo -
notherapy, IPC produced a highly significant 66%
reduction in DVT (112/1108 [10.1%] IPC vs. 268/
1147 [23.4%] control, p< 0.00001). There was mar-
ginal evidence of heterogeneity of effect among these
trials (df = 28.4; p = 0.03), but this was generated
chiefly by one trial.
There is a lack of large RCTs evaluating whether
a combination of mechanical methods might be more
effective than a single mechanical method in prevention
of DVT in post-stroke patients. The results of the ongo-
ing large randomized trial CLOTS 3, which aims to
compare the effectiveness of IPC vs. none in over 2800
stroke patients, will be available in May 2013 [44].
The first, small study evaluating the effectiveness 
of physical methods in preventing VTE was published
in 1982. This study [45] included patients within 
72 hours of having an acute stroke. The total number
of included subjects was 26. Patients were randomized
(method unclear) to receive an intermittent pneumatic
compression device or not for 10 days. The diagnosis of
DVT was provided by use of 125-I-fibrinogen. The test
was performed within 24 hours of admission to hospi-
tal and scanning of the precordium and leg was carried
out for 10 days. It was not clear whether the fibrinogen
scans were assessed blind to the treatment allocation.
The dia gnosis of DVT proved by 125-I-fibrinogen scan
was confirmed in 12 patients out of 26 (46%). Clinical
signs of DVT were observed in only one patient with
a positive scan although it is unclear which treatment 
this patient received. There were no significant differ-
ences in the radio-isotopic incidence of DVT between
the treatment and control group (6 patients vs. 6 patients,
p = ns).
A more recent trial randomized 151 patients (from
February 2002 to December 2003) with an intracere-
bral haemorrhage, within 48 hours since the onset, to
elastic stockings (GCS) alone (77 patients) or combined
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GCS + IPC (74 patients). The primary outcome was
assessed at day 10 and included a symptomatic and well-
documented VTE, or a death arising before day 10 due
to pulmonary embolism, or an asymptomatic DVT 
of the lower limbs detected by compression ultrasono -
graphy (CUS). Outcome assessment was blinded. 
133 (88%) patients were evaluated at day 10. No clini-
cal suspicion of VTE arose before day 10. Fourteen
patients died before CUS check but no death was def-
initely related to PE. Fourteen asymptomatic DVTs were
detected by CUS: three (4.7%) in the GCS + IPC
group (all distal) and 11 (15.9%) in the GCS group
(three proximal and eight distal), relative risk (RR) 0.29
(95% CI: 0.08 to 1.00). Absolute risk reduction was
0.11 (95% CI: 0.00-0.22). The failure to follow up 12%
of patients and imprecise estimate of effect, which was
mainly based on distal DVTs (CUS has low sensitivity
in reliable detection in that region), means that this trial
cannot be regarded as adequate evidence on which to
base treatment [46].
Another study [47] monitored the rate of DVT
among non-haemorrhagic stroke patients admitted to
their neurology service from October 1988 to June
1996. For part of this period some patients (249 in total)
received just 5,000 U subcutaneous heparin twice dai-
ly and antiembolic hose. Another group of 432 non-
ambulatory stroke patients had sequential pneumatic
compression devices applied to both legs in addition to
subcutaneous heparin and antiembolic hose. DVT pro-
phylaxis was started within 12 hours of admission. Twen-
ty-three of 249 patients (9.2%) treated with heparin
alone developed DVT and six of those patients (2.4%)
developed PE. Only one DVT (0.23%) and no PEs
occurred among the 432 patients treated with sequen-
tial pneumatic compression devices + subcutaneous
heparin + antiembolic hose. Clearly, this non-random-
ized trial is very prone to bias but it does suggest that
the treatment is practical and acceptable to patients.
The large ongoing trial CLOTS 3 (2800 patients
will be recruited to IPC or not) aims to determine
whether it is effective in stroke patients [44].
Despite the poor evidence, IPC devices are rec-
ommended by both European and American guide-
lines in both ischaemic and haemorrhagic stroke
patients [17,18]. Polish guidelines do not mention this
method of VTE prophylaxis [21]. Most recent Polish
recommendations accepted from ACCP guidelines
accept the use of IPC in haemorrhagic stroke patients,
and in ischaemic stroke patients as an addition to
heparins [19]. 
Summary of current 
recommendations
• Heparins are the preferred method of VTE prophyla -
xis in both ischaemic and haemorrhagic stroke patients. 
• LMWH are preferred over UFH.
• GCS are not recommended routinely in both is chae -
mic and haemorrhagic stroke patients. 
• VTE prophylaxis in immobile patients with acute
haemorrhagic stroke should be started 2-4 days after
stroke onset.
• Adding IPC to heparins may provide additional ben-
efit in preventing VTE in stroke patients.
Detailed Polish recommendations have been com-
piled in the newest version of those recommendations
published in 2012 (see: Z6-53A to Z6-54C) [19].
Conclusions
In summary, there are several different methods
which aim to reduce the risk of VTE. Not all of them
seem to be effective. Heparins are recommended as
a method of choice to prevent thromboembolic compli-
cations in stroke patients. However, there is no gold
standard method for all post-stroke patients to prevent
VTE. Inevitably, where reliable evidence is not avail-
able, variation in recommendations and clinical practice
exists [17-19,21,48,49]. 
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